Today 100 GPAINNOVA’s RESPIRA emergency ventilators have been delivered to the SEM to continue clinical trial with patients affected by COVID-19 in other hospitals

April 21 00:39 2020

Barcelona – April 20th, 2020 – Representatives of Hospital Clínic, Hospital i Institut de RecercaGermans Trias i Pujol and GPAINNOVA have delivered the first 100 RESPIRA emergency ventilation devices to Centre

d’Operacions Logístiques that has been launched by the Sistema d’Emergències Mèdi-ques (SEM). The device has already passed the first phase of the clinical study and, with this donation, it can be distributed to other hospitals in Catalonia, depending on the needs, and the trial can be expanded.

This initiative, along with other prototypes of respirators, has been possible thanks to the support received by a large number of individuals, companies and civil society entities that, through the Fundació Clínic per a la Recerca Biomèdica, have contributed resources. It has also had the support of Servei Català de la Salut, which has encouraged the incorporation of companies and has supported centers to find this kind of solution.

Clinical trial was carried out with two patients at Hospital Clínic, who have received support for breathing with positive results. These are patients who otherwise would not have had this support. Once the first phase of the clinical trial has been approved, this trial can be extended to other hospitals in the health system.

How does emergency ventilator work?

RESPIRA device automates manual resuscitation devices (BMV or AMBU), currently widely available in medical centers, and allowed to attend mechanically to the patient.

It has features that allows real-time monitoring of patient’s variables in a personalized way and control them remotely to facilitate their management in hospitals.

Device incorporates the necessary electronics to remotely control variables such as the frequency and volume of air and pressure supplied to the patient, provided by SIEMENS, and a precision drive device manufactured by SMC. The use of a control station allows managing up to 16 devices simultaneously through its own Wi-Fi network.

Collaborative development


Pau Sarsanedas (GPAINNOVA), Dr. Josep M. Nicolás (Clínic), Dr. Oriol Estrada (Can Ruti), Dr. Josep M. Campistol (Clínic).

On Tuesday, March 31st, validation tests ended at Hospital Clínic of Barcelona with a simulator and on April 1st they were tested in animals, at Centre de Medicina Comparativa i Bioimatge (CMCiB) de l’Institut de Recerca Germans Trias i Pujol. At the same time, as established by AEMPS guidelines, electromagnetic com-patibility tests have been carried out to ensure that the device does not interfere with other devices and medical equipments. After authorization from AEMPS, the clinical trial began with patients affected by COVID-19.

PRESS CONTACT

Press GPAINNOVA:

Betona Comín
Tel. 607 29 11 05
E-Mail: [email protected]

Press RESPIRA Project:

Jordi Miras Llopart
Tel. 678 43 98 39
E-Mail: [email protected]

Materials, photos and videos link:

https://www.dropbox.com/sh/5sqws0eup81qp4r/AAAJDR1twL3Z2et6vYUnwYxja?dl=0

INQUIRIES AND ORDERS RESPIRA

Web RESPIRA: www.respiradevice.com

E-mail: [email protected] | Tel.: (+34) 93 125 65 36

Catalan company MAM collaborates in the industrialization and production, which is carried out in Santa Perpetua de Mogoda factory.

Media Contact
Company Name: GPAInnova
Contact Person: Media Relations
Email: Send Email
Phone: (+34) 93 125 65 36
Country: Spain
Website: https://www.respiradevice.com/